SOIKEN HOLDINGS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 170 JPY | +1.19% |
|
+0.59% | +1.19% |
| Sales 2024 * | 8.58B 54.7M 4.56B | Sales 2025 * | 8.97B 57.18M 4.77B | Capitalization | 4.39B 28.02M 2.34B |
|---|---|---|---|---|---|
| Net income 2024 * | 610M 3.89M 324M | Net income 2025 * | 660M 4.21M 351M | EV / Sales 2024 * | 0.51 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.49 x |
| P/E ratio 2024 * |
7.2
x | P/E ratio 2025 * |
6.66
x | Employees | 98 |
| Yield 2024 * |
3.57% | Yield 2025 * |
4.17% | Free-Float | 61.06% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.19% | ||
| 1 week | +0.59% | ||
| Current month | +4.94% | ||
| 1 month | -10.99% | ||
| 3 months | +1.19% | ||
| 6 months | -18.27% | ||
| Current year | +1.19% |
1 week
167.00
174.00
1 month
163.00212.00
Current year
139.00212.00
1 year
139.00315.00
3 years
139.00563.00
5 years
139.001 054.00
10 years
112.001 054.00
| Managers | Title | Age | Since |
|---|---|---|---|
Osamu Tanabe
DFI | Director of Finance/CFO | 53 | 01/03/01 |
Kentaro Ishigami
PSD | President | 51 | 01/05/01 |
Kazuhiro Hayashi
PSD | President | 71 | 01/01/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Osami Kajimoto
FOU | Founder | 62 | 01/94/01 |
Osamu Tanabe
DFI | Director of Finance/CFO | 53 | 01/03/01 |
Tomoaki Sugino
BRD | Director/Board Member | 55 | 01/03/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 170 | +1.19% | 11 100 |
| 26/24/26 | 168 | -1.18% | 12,800 |
| 25/24/25 | 170 | +1.19% | 20,900 |
| 24/24/24 | 168 | -0.59% | 75,000 |
| 23/24/23 | 169 | +0.60% | 38,400 |
Delayed Quote Japan Exchange, April 30, 2024 at 07:33 am IST
More quotes
Soiken Holdings Inc. is a Japan-based holding company. The Company operates in six business segments. The Biological Evaluation System segment is engaged in evaluation test of food and research support of medicine. The Healthcare Support segment is engaged in the provision of service about certain health guidance and healthcare insurance. The Cosmetics segment is engaged in manufacturing and sales of cosmetics. The Dietary Supplements segment is engaged in sales of unique dietary supplements. The Marketing segment is engaged in the marketing research of health supplement and sales of energy drink. The Functional Material Development segment is engaged in development and sales of functional materials, such as lactoferrin.
Sector
Personal Products
Calendar
13/05/2024
- Q3 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.19% | 27.92M | |
| +12.10% | 18.86B | |
| 0.00% | 17.37B | |
| -0.66% | 10.65B | |
| -7.25% | 10.26B | |
| +7.52% | 6.72B | |
| +10.34% | 5.94B | |
| -0.06% | 4.55B | |
| -18.21% | 3.83B | |
| -3.97% | 3.48B |
- Stock Market
- Equities
- 2385 Stock
